The U.S. Food and Drug Administration (FDA) has approved finerenone to treat patients with heart failure (HF) with LVEF ≥40%. The approval was based on results from the FINEARTS-HF trial, presented at ...
Digitoxin in addition to guideline-directed medical therapy, reduced the risk of a composite of all-cause death and hospitalization for worsening heart failure (HF) among patients with advanced HF and ...
As the new year begins, the landscape of cardiovascular medicine is undergoing a remarkable transformation, driven by groundbreaking technologies and innovative approaches that promise to ...
The One Big Beautiful Bill Act (OBBBA) became law on July 4, cutting more than $1 trillion in Medicaid funding and making substantial changes to the federal student loan program. When the U.S. House ...
The U.S. Food and Drug Administration (FDA) has approved the FARAPULSE Pulsed Field Ablation System for isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic, ...
The 2023 European Society of Hypertension (ESH) and 2017 American College of Cardiology/American Heart Association (ACC/AHA) hypertension guidelines both emphasize proper blood pressure (BP) ...
The U.S. Food and Drug Administration (FDA) announced on April 15 that Abbott/Thoratec Corp. is recalling the Heartmate II and Heartmate 3 Left Ventricular Assist System (LVAS) due to long-term ...
The Centers for Medicare and Medicaid Services (CMS) released the 2025 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgery Center (ASC) final rule on Nov. 1. The rule will ...
Persistent symptoms after an acute pulmonary embolism (PE) may indicate post-pulmonary embolism syndrome (PPES), a condition affecting up to 50% of patients. The most important consideration in ...
TRANSFORMING CARDIOVASCULAR CARE FOR ALL STARTS HERE! Join the American College of Cardiology (ACC) and the ACC Mexico Chapter for ACC Latin America 2025. Designed to elevate your practice and deliver ...
A new nasal spray form of bumetanide may reduce the tissue swelling caused by heart failure (HF) as effectively as the standard oral and intravenous formulations of the loop diuretic, based on ...
The proposed 2026 Medicare Physician Fee Schedule (PFS) includes a proposal to reduce the physician work relative value unit (RVU) for performing a left atrial appendage closure procedure (LAAO) from ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback